Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

60.72 +1.79 (+3.03%)

Streaming Delayed Price Updated: 12:47 PM EST, Feb 17, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

38 39 Next >

In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit Cluster ↗

April 04, 2024

Sanofi reaches a settlement in principle for about 4,000 Zantac lawsuits in the US, excluding Delaware, regarding alleged cancer risks linked to NDMA. Financial terms remain undisclosed.

Via Benzinga

Topics Lawsuit

2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? ↗

April 03, 2024

These stocks could rocket higher, but they also present significant risks.

Via The Motley Fool

Russell 2000 Index Best And Worst Performing Stocks Of 2024 ↗

April 02, 2024

The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024.

Via Talk Markets

Topics Stocks

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback ↗

March 28, 2024

The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.

Via Investor's Business Daily

Peering Into GSK's Recent Short Interest ↗

March 26, 2024

Via Benzinga

Looking Into GSK's Recent Short Interest ↗

February 12, 2024

Via Benzinga

Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead? ↗

March 24, 2024

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

Via The Motley Fool

Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗

March 21, 2024

GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid...

Via Benzinga

GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial Cancer ↗

March 18, 2024

Latest advancements in endometrial cancer treatment with GSK's Jemperli (dostarlimab)! Explore promising overall survival and progression-free survival results from the RUBY trial, paving the way for...

Via Benzinga

Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B ↗

March 18, 2024

Pfizer to reduce stake in Haleon to approximately 24% following earlier divestment announcement. Offer price per share to be revealed post book-building process by Haleon.

Via Benzinga

Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗

March 13, 2024

One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses.

Via InvestorPlace

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead ↗

March 11, 2024

Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.

Via InvestorPlace

Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗

March 11, 2024

Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets.

Via Benzinga

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗

March 07, 2024

Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.

Via InvestorPlace

GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage Study ↗

March 07, 2024

GSK's DREAMM-8 trial reveals positive interim results for Blenrep combo in relapsed multiple myeloma. Improved progression-free survival and overall survival trend observed.

Via Benzinga

Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows ↗

March 06, 2024

Findings from ViiV Healthcare's LATITUDE trial on long-acting HIV treatment. Cabenuva demonstrates superior efficacy in viral load suppression compared to daily oral therapy. Key secondary endpoints...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

March 06, 2024

Via Benzinga

Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says ↗

March 05, 2024

WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized...

Via Benzinga

Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal Challenges ↗

March 04, 2024

The Biden administration wants insurers to cover preventive care, facing opposition from businesses led by Braidwood Management.

Via Benzinga

Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock Soars ↗

February 29, 2024

Haleon reports FY 2023 revenue growth of 4.1% to £11.3 billion ($14.03 billion), missing consensus. Adjusted operating profit rises 10.4% to £2.55 billion. CEO Brian McNamara outlines solid financial...

Via Benzinga

GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A Month ↗

February 29, 2024

GSK settles California lawsuits over Zantac cancer allegations. Confidential agreements reached, cases dismissed.

Via Benzinga

Topics Lawsuit

11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗

February 28, 2024

A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.

Via Benzinga

GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted Infection ↗

February 26, 2024

Results from GSK's EAGLE-1 phase 3 trial on gepotidacin, an oral antibiotic for uncomplicated urogenital gonorrhea. Non-inferior to leading treatment, it offers a potential solution amid rising...

Via Benzinga

3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List ↗

February 22, 2024

Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.

Via InvestorPlace

Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report ↗

February 22, 2024

The company unexpectedly came in with fourth-quarter earnings that beat projections.

Via Investor's Business Daily

Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus ↗

February 21, 2024

Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024.

Via Benzinga

3 Low-Priced Dividend Stocks With Solid Fundamentals & Growth ↗

February 21, 2024

Solid dividend stocks with good growth outlooks can deliver high profits for investors and should become more popular as interest rates drop.

Via InvestorPlace

Dividend Income Update January 2024 ↗

February 15, 2024

It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio

Via Talk Markets

Why Is Moderna Stock Trading Lower Today? ↗

February 09, 2024

Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.

Via Benzinga

Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?' ↗

February 06, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer believes in GSK plc (NYSE: GSK).

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.